- Home
- COCP vs LPCN Comparison
COCP vs LPCN Comparison
Compare COCP & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCP
- LPCN
- Stock Information
- Founded
- COCP 2006
- LPCN 1997
- Country
- COCP United States
- LPCN United States
- Employees
- COCP N/A
- LPCN N/A
- Industry
- COCP Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- COCP Health Care
- LPCN Health Care
- Exchange
- COCP Nasdaq
- LPCN Nasdaq
- Market Cap
- COCP 15.4M
- LPCN 18.2M
- IPO Year
- COCP N/A
- LPCN N/A
- Fundamental
- Price
- COCP $1.22
- LPCN $3.20
- Analyst Decision
- COCP Strong Buy
- LPCN Strong Buy
- Analyst Count
- COCP 1
- LPCN 1
- Target Price
- COCP $6.00
- LPCN $8.00
- AVG Volume (30 Days)
- COCP 4.6M
- LPCN 26.9K
- Earning Date
- COCP 11-12-2025
- LPCN 11-06-2025
- Dividend Yield
- COCP N/A
- LPCN N/A
- EPS Growth
- COCP N/A
- LPCN N/A
- EPS
- COCP N/A
- LPCN N/A
- Revenue
- COCP N/A
- LPCN $4,208,119.00
- Revenue This Year
- COCP N/A
- LPCN N/A
- Revenue Next Year
- COCP N/A
- LPCN N/A
- P/E Ratio
- COCP N/A
- LPCN N/A
- Revenue Growth
- COCP N/A
- LPCN N/A
- 52 Week Low
- COCP $1.12
- LPCN $2.65
- 52 Week High
- COCP $3.26
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- COCP 37.81
- LPCN 61.58
- Support Level
- COCP $1.17
- LPCN $2.65
- Resistance Level
- COCP $1.31
- LPCN $2.83
- Average True Range (ATR)
- COCP 0.09
- LPCN 0.17
- MACD
- COCP -0.00
- LPCN 0.06
- Stochastic Oscillator
- COCP 20.00
- LPCN 63.22
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.